Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: EXAS stock price vs REGN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at REGN's multiple
Needs REGN P/S.
Implied fair value · at EXAS's multiple
Needs Revenue / share, EXAS P/S.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Ten period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
EXACT SCIENCES CORP · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
REGENERON PHARMACEUTICALS, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Guardant Health, Inc.
EXAS vs GH
Natera, Inc.
EXAS vs NTRA
NEOGENOMICS INC
EXAS vs NEO
OPKO HEALTH, INC.
EXAS vs OPK
LABCORP HOLDINGS INC.
EXAS vs LH
QUEST DIAGNOSTICS INC
EXAS vs DGX
AMGEN INC
EXAS vs AMGN
PFIZER INC
EXAS vs PFE
BRISTOL MYERS SQUIBB CO
EXAS vs BMY
BIOGEN INC.
EXAS vs BIIB
GILEAD SCIENCES, INC.
EXAS vs GILD
Seagate Technology Holdings plc
EXAS vs STX
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe EXAS can convert its 17.7% revenue growth and 69.7% gross margin into sustained positive operating income, then the implied $85.01 valuation case becomes more credible because the current comparison still shows REGN as the clearly more profitable REGN.
The provided valuation work implies EXAS at $85.01, with REGN-implied range spanning $9.59 to $85.01, placing EXAS at the top end of the cited range. Because the comparison lacks a current price and EXAS has no listed P/E or EV-based multiples, the gap is framed mainly through a P/S lens rather than earnings power.
Supporting Metrics
